Navigation Links
OncoMed Pharmaceuticals Awarded Five Therapeutic Discovery Project Grants Totaling $1.2 Million
Date:11/2/2010

REDWOOD CITY, Calif., Nov. 2, 2010 /PRNewswire/ -- OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells, announced today that it has been awarded $1.2 million to support five distinct therapeutic programs under the U.S. Government's Qualifying Therapeutic Discovery Project ("QTDP") program.  All of the grant applications submitted by the company received an award.  The funds will be used to continue development of each of five promising therapeutic programs.

"The QTDP program provides our industry with needed capital to maintain the U.S.'s lead in biomedical innovation, support the development of breakthrough medical discoveries, sustain industry growth, and improve the time and speed of the FDA and CMS in getting life-saving medicines to people.  This will in turn enhance the willingness of private and public investors to fund these projects and companies, thus creating jobs and better quality healthcare for all Americans," said Paul Hastings, President and Chief Executive Officer of OncoMed Pharmaceuticals.  "We are pleased to see OncoMed recognized by the award of these QTDP Program grants, which value the scope of our research and emerging pipeline of anti-cancer stem cell therapeutics programs.  We look forward to applying these funds to development candidates arising from our insights into multiple cancer stem cell pathways and cancer biology."

The Qualifying Therapeutic Discovery Project Program was created by Congress as a temporary tool to support innovation and job creation by biotech companies.  Under the QTDP program, a total of $1 billion in grants or tax credits was made available to companies with 250 employees or fewer.  Grants may cover up to 50 percent of the costs of qualifying biomedical research and only one credit may be awarded per therapeutic product.  To be eligible for the program, projects must show reasonable potential to do the following: result in new therapies to treat areas of unmet medical need; prevent, detect, or treat chronic or acute disease and conditions; reduce long-term health care costs; or significantly advance the goal of curing cancer within a 30-year period.  Projects were selected jointly by the Treasury Department and the Department of Health and Human Services.

About Cancer Stem Cells

Cancer stem cells, a small, resilient subset of cells found in tumors, have the capacity to self-renew and differentiate, leading to tumor initiation and driving tumor growth, recurrence and metastasis.  Also referred to as "tumor-initiating cells," these cells were first discovered by OncoMed's scientific founders in breast cancer and have subsequently been identified in many other types of solid tumor cancers, including cancer of head and neck, lung, prostate, pancreas, and glioblastoma.  Cancer stem cells appear to be preferentially resistant to both standard chemotherapy and radiotherapy.  OncoMed's strategy is to improve cancer treatment by specifically targeting the key biologic pathways which are thought to be critical to the activity and survival of cancer stem cells.  OncoMed's antibody therapeutics target cancer stem cell proteins and have the potential to be developed against a range of tumor types.  

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage company that discovers and develops novel therapeutics targeting cancer stem cells, the cells believed to be capable of driving tumor growth, recurrence and metastasis.  A leader in cancer stem cell research, the company has established a library of antibodies to cancer stem cell proteins for the treatment of solid tumors such as pancreatic, breast, colorectal and lung cancers.  OncoMed's lead candidate, OMP-21M18, is currently in Phase Ib clinical trials.  In addition to OMP-21M18, OncoMed's pipeline includes several novel preclinical product candidates targeting multiple validated cancer stem cell pathways.  OncoMed has formed strategic alliances with Bayer Schering Pharma and GlaxoSmithKline.  Privately-held, OncoMed's investors include:  US Venture Partners, Latterell Venture Partners, The Vertical Group, Morgenthaler Ventures, Nomura Phase4 Ventures, Delphi Ventures, Adams Street Partners, De Novo Ventures, Bay Partners and GlaxoSmithKline.  Additional information can be found at the company's website: www.oncomed.com.


'/>"/>
SOURCE OncoMed Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bayer and OncoMed Pharmaceuticals Enter Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
2. SynCo Expands Agreement with OncoMed Pharmaceuticals to Manufacture Cancer Stem Cell Antibodies
3. OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
4. Transcept Pharmaceuticals to Report Third Quarter 2010 Results and Host Conference Call on November 11, 2010
5. Anthera Pharmaceuticals Reports 2010 Third Quarter Financial Results and Operational Update
6. ISTA Pharmaceuticals Reports Third Quarter 2010 Financial Results
7. DUSA Pharmaceuticals, Inc.® to Host Third Quarter 2010 Corporate Highlights and Financial Results Conference Call
8. Access Pharmaceuticals Awarded $1.5 Million in Section 48D Grants
9. Anadys Pharmaceuticals to Report Third Quarter 2010 Financial Results
10. Alder Biopharmaceuticals Appoints Bruce Montgomery to Board of Directors
11. Alexza Pharmaceuticals to Announce 2010 Third Quarter Financial Results on November 9, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... , May 10, 2017 CSSi, the global ... the clinical research industry, is proud to announce the ... The new website features both enriched content and a ... and enhances the company,s already well-established position as the ... "After many months of hard work, we ...
(Date:5/9/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... on the development of oral drug delivery systems, ... has granted Oramed a patent titled, "Methods and ... covers Oramed,s invention of an oral glucagon-like peptide-1 ... hormone that stimulates the secretion of insulin from ...
(Date:5/8/2017)... May 8, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO)., ... ("WRB"), a health care service center company based ... WRB specializes in relationship management programs for leading pharmaceutical ... WRB will join Envoy Health ... services for manufacturers, biotech firms, and other service companies. ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... ... a new educational seminar to focus on current legislative activity and the latest ... begin at 1 p.m. Sunday, Sept. 10, and will continue through Monday, Sept. ...
(Date:5/26/2017)... ... May 26, 2017 , ... Somnoware, ... NOX-T3 portable sleep monitor with its Somnoware Sleep Device Interface (SDI). Somnoware SDI ... diagnostic device operations. With this platform, initializing devices and importing studies are just ...
(Date:5/26/2017)... ... May 26, 2017 , ... Boar’s Head Brand®, one of ... Memorial Day entertaining that are sure to satisfy your guests’ flavor cravings, while ... and cheeses featured in these refreshingly balanced recipes are packed with flavor, creating ...
(Date:5/26/2017)... , ... May 26, 2017 , ... On May 24, ... which narrowly passed the U.S. House on May 4, would result in 23 million ... under continued implementation of the 2010 Patient Protection and Affordable Care Act (ACA). ...
(Date:5/26/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh ... the Peace Agreements being discussed by President Donald Trump and the rest of the ... to speed up peace talks in the continuous battle between Israel and Palestine. The ...
Breaking Medicine News(10 mins):